(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > Facultad de Farmacia > Departamento de Farmacia y Tecnología Farmacéutica > DA - Farmacia - Tecnología Farmacéutica - Artículos de revista >

Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy
Autor(es) : Gurpide, A. (Alfonso)
Sadaba, B. (Belén)
Martin-Algarra, S. (Salvador)
Azanza, J.R. (José Ramón)
Lopez-Picazo, J.M. (José M.)
Campanero, M.A. (Miguel Angel)
Cabello, J.P. (J.P.)
Gil-Aldea, I. (I.)
Cruz, S. (S.) de la
Fernandez-Gallego, V. (V.)
Reyna, C. (Carmen)
Olier, C. (Clara)
Blanco-Prieto, M.J. (María José)
Ceballos, J. (J.)
Garcia-Foncillas, J. (Jesús)
Perez-Gracia, J.L. (José Luis)
Palabras clave : Emesis
Granisetron
Pharmacokinetics
Subcutaneous
Fecha incorporación: 2007
Editorial : AlphaMed Press
Versión del editor: http://dx.doi.org/10.1634/theoncologist.12-9-1151
ISSN: 1083-7159
Cita: Gurpide A, Sadaba B, Martin-Algarra S, Azanza JR, Lopez-Picazo JM, Campanero MA, et al. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy. Oncologist. 2007 Sep;12(9):1151-5.
Resumen
BACKGROUND: 5-HT3-receptor antagonists are one of the mainstays of antiemetic treatment, and they are administered either i.v. or orally. Nevertheless, sometimes neither administration route is feasible, such as in patients unable to admit oral intake managed in an outpatient setting. Our objective was to evaluate the bioavailability of s.c. granisetron. PATIENTS AND METHODS: Patients receiving platinum-based chemotherapy were randomized to receive 3 mg of granisetron either s.c. or i.v. in a crossover manner during two cycles. Blood and urine samples were collected after each cycle. Pharmacokinetic parameters observed with each administration route were compared by analysis of variance. RESULTS: From May to November 2005, 31 patients were included and 25 were evaluable. Subcutaneous granisetron resulted in a 27% higher area under the concentration-time curve for 0-12 hours (AUC(0-12h)) and higher levels at 12 hours, with similar values for AUC(0-24h). The maximum concentration was lower with the s.c. than with the i.v. route and was observed 30 minutes following s.c. administration. CONCLUSION: Granisetron administered s.c. achieves complete bioavailability. This is the first study that shows that s.c. granisetron might be a valid alternative to i.v. delivery. Further trials to confirm clinical equivalence are warranted. This new route of administration might be especially relevant for outpatient management of emesis in cancer patients.
Enlace permanente: http://hdl.handle.net/10171/19115
Aparece en las colecciones: DA - CUN - Oncología médica - Artículos de revista
DA - CUN - Farmacología clínica - Artículos de revista
DA - Farmacia - Tecnología Farmacéutica - Artículos de revista

Ficheros en este registro:
Fichero:  Blanco-PrietoOnc2007.pdf
Descripción: 
Tamaño:  222,27 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.